Navigation Links
AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
Date:12/13/2012

t product development programs include fostamatinib, an oral SYK inhibitor that is in Phase III clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase II clinical trials; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders. Visit www.rigel.com.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

Rigel Pharmaceuticals Forward Looking Statement
This press release contains "forward-looking" statements, including, without limitation, statements related to the progress of the development of fostamatinib, partnered with AstraZeneca, and the results of OSKIRA-4, as well as statements related to dates for clinical filings and publications. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "hypothesized," "will," "may," "expect," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, the timing and success of clinical trials and the p
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
3. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
4. AstraZeneca Acquires Neuroscience Assets From Link Medicine
5. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
6. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
9. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
11. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... YORK , May 18, 2013 ... law firm, is investigating potential securities fraud at ... AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... Company and its executives violated federal securities laws ... the Company,s Phase III drug trials for Tivopath ...
(Date:5/17/2013)... -- Medical devices are any medical items that are ... of their different mechanisms, actions and regulatory requirements, medical ... drug trails due to their unique clinical practices. Currently, ... both safety and efficacy (which is left to the ... as the SFDA) evaluate MDs for both safety and ...
(Date:5/17/2013)... 17, 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; ... Technology Small Business Technology Transfer Research (STTR) grant ... Infectious Diseases (NIAID), a division of the National ... novel human antibody therapeutics to combat Staphylococcus ... infections, including methicillin-resistant S. aureus (MRSA), ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4
... DALLAS , March 22 Texas Instruments Incorporated ... in a family of fully integrated analog front ends (AFEs) ... (EEG) equipment, as well as patient monitoring and consumer medical ... and power consumption by up to 95 percent as compared ...
... , March 22 Galderma Laboratories, L.P. today announced the U.S. Food and Drug Administration (FDA) approval of Differin® (adapalene) Lotion, 0.1%, ... April 2010 . , ... , ... ...
Cached Medicine Technology:Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 2Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 3Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 4Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 5Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 6Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 7Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 2Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 3Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 4Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 5Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 6Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 7
(Date:5/19/2013)... People in Minnesota have a great option ... offering its 28 Day Fat Loss Formula. The best ... of their own home. The product sells for $135 dollars ... be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is ... now, but after using the 28 Day Fat Loss Formula ...
(Date:5/19/2013)... New York, New York (PRWEB) May 19, 2013 ... move forward in a federal litigation now underway in ... to a Case Management Order dated May 3rd, the ... the Bellwether Nominee Pool to eight cases rather than ... litigation is scheduled for Thursday, May 23rd. (In re: ...
(Date:5/19/2013)... Park City, Utah (PRWEB) May 19, 2013 ... new information on small business health insurance ... alternatives to traditional employer sponsored health benefits, is ... contribution and health reimbursement arrangements . ... businesses, start-ups, and the self-employed intrinsically know the ...
(Date:5/19/2013)... According to a new market research ... – 2018): By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), ... Contact IS, Infrared, X-Ray) And Geography" published by ... $8.00 billion in 2012 and is expected to ... CAGR of 3.84% from 2013 to 2018. In ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 These ... for US, UK, Spain, Japan, Italy, Germany and ... the molecular diagnostics laboratory practice, as well as ... with significant market impact during the next five ... probe and biochip technologies, test formats, detection methodologies, ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4
... Drizzled with Pink White-Chocolate, CHICAGO, Oct. 8 ... announce its new Pink Ribbon Pretzel available throughout,October, ... resources and emotional support to those touched by,breast ... of,the breast cancer awareness ribbon, and topped with ...
... in the elderly increases the risk of subsequent mental ... intellectual decline, University of Rochester Medical Center psychiatrists and ... or prevention of depression would reduce or prevent cognitive ... that would be our hope, said Jeffrey M. Lyness, ...
... risk, experts say , , MONDAY, Oct. 8 (HealthDay News) -- ... fertilizer, according to a new study that finds human urine ... , The "yuck" factor aside, scientists who used urine to ... may not be a bad idea. , "Urine is a ...
... YORK, Oct. 8 Forest Laboratories, Inc.,(NYSE: ... pharmaceutical,products, will release its Fiscal 2008 Second Quarter ... Tuesday, October 16, 2007. Later that,day, at 10:00 ... where Dr. Lawrence,Olanoff, President and Chief Operating Officer ...
... busy fall season in,full swing, Hands2GO(R), the nation,s first ... against this year,s winter,cold and flu season. Typically, the ... "Regular hand washing, combined with Hands2GO hand sanitizers and ... year," said Francine,Glick, CEO and founder of Hands2GO. "It,s ...
... on the Internet: Thursday, October 11, 2007, 9 AM-4:00 PM, ... on employer-sponsored wellness programs that will work ... new economic model to address overweight and ... well as employers, e.g. Mayo Clinic, Hannaford ...
Cached Medicine News:Health News:Kim & Scott's Gourmet Pretzels(TM) Supports Breast Cancer Organizations With Its New Pink Ribbon Pretzel 2Health News:Depression can foreshadow intellectual decline in older people 2Health News:Human Urine Safe, Productive Fertilizer 2Health News:Human Urine Safe, Productive Fertilizer 3Health News:Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings 2Health News:Hands2GO(R) Hand Sanitizer Offers Alcohol-Free Alternative to Stopping the Spread of Flu at School and Work 2Health News:Hands2GO(R) Hand Sanitizer Offers Alcohol-Free Alternative to Stopping the Spread of Flu at School and Work 3Health News:Webcast Alert: Expert Group Urges Businesses to Get Real About Weight Loss 2
... The instrument includes the ... has increased illumination for ... illumination. The Copeland retinoscope ... handle, and extended battery ...
... stereopsis from 800 to 40 ... young as 2 years of ... from left to right., ,Randot ... Book #1: 200 & 100 ...
... EasyEye is the only handheld non-contact tonometer with ... is streamlined, quiet and now, with constant ... a gentle puff of air. You can prove ... on the patient's hand before you start. ...
... 2000 Phenytoin Assay is a ... use in the quantitative analysis ... or plasma. Kits are packaged ... Roche COBAS MIRA, COBAS MIRA ...
Medicine Products: